JOURDANLABSTransaction math without banker theater.
ALCHEMIST Merger frames an acquisition from source-backed inputs: offer premium, consideration mix, financing, pro forma share count, synergy bridge, and EPS accretion or dilution. It makes the arithmetic legible while refusing legal conclusions and fairness opinions. This page is backed by a deterministic API runner, not a fairness opinion or production deal committee.
22.0%
Calculated against unaffected target price.
65% cash / 35% stock
Sources and uses reconcile to purchase equity value.
-1.8%
Dilutive before full run-rate synergies.
High
Accretion turns positive only after 80% realization.
A deterministic screen for deal structure.
The model computes transaction mechanics before narrative takes over. It shows what must be true for accretion, where synergies carry the case, and which inputs are unsupported, then stops short of board, legal, tax, and fairness judgments.
COPYABLE MERGER PACKET Acquirer: Atlas Health Systems Target: Meridian Diagnostics Transaction: Public-company acquisition, 65% cash / 35% stock Fiscal periods: Acquirer CY2026E consensus EPS; target LTM EBITDA through Q1 2026; Year 1 pro forma CY2027E Source references: - Atlas CY2026E consensus tear sheet dated 2026-04-12: https://ir.atlashealth.example/consensus/cy2026 - Meridian Form 10-K filed 2026-02-20 and Q1 2026 Form 10-Q filed 2026-05-08: https://investors.meridiandiagnostics.example/sec - Draft merger model v5, "Sources_Uses" and "EPS Bridge" tabs, received 2026-05-14 - Bank financing term sheet dated 2026-05-15; legal, tax, antitrust, and fairness materials not supplied Source facts and assumptions: - Acquirer CY2026E standalone EPS: $5.25 - Acquirer diluted shares: 220.0mm; acquirer share price: $75.00 - Target diluted shares: 75.0mm; target net debt assumed $420.0mm for enterprise-value bridge only - Offer price: $48.80 per target share - Unaffected target share price: $40.00 as of 2026-04-03, the last close before reported transaction rumors - Cash consideration: 65.0% of equity purchase price - Stock consideration: 35.0% of equity purchase price, issued at acquirer share price - New debt coupon: 6.5%; upfront fees excluded from EPS bridge - Cash tax rate: 25.0% - Year 1 cost synergies: $0.0mm unless supplied; Year 2 pre-tax run-rate synergies: $120.0mm at 75.0% realization in the EPS bridge - Transaction expenses, purchase accounting, amortization step-up, and integration capex are not supplied Screen rules: - Compute offer premium, equity purchase price, cash paid, stock issued, after-tax interest, and EPS impact. - Treat Year 1 synergies as $0 unless specifically supplied. - Flag any accretion case that depends on unsupplied run-rate synergies, purchase accounting, or cost of debt. - ABSTAIN on fairness, board recommendation, antitrust, tax structuring, financing certainty, and definitive agreement interpretation.
A compliant answer should compute dilution before run-rate synergies, show the exact financing bridge, and refuse any fairness or board recommendation.
ALCHEMIST MERGER OUTPUT Acquirer: Atlas Health Systems Target: Meridian Diagnostics Offer: $48.80 per target share Unaffected target price: $40.00 Source receipts: Atlas consensus tear sheet dated 2026-04-12; Meridian 2026 10-K / Q1 2026 10-Q; draft merger model v5; 2026-05-15 financing term sheet Fiscal basis: CY2026E standalone acquirer EPS; Year 1 pro forma CY2027E; Year 2 synergy case shown separately Assumption mode: deterministic API runner using supplied packet facts only; no live market feed, fairness engine, legal review, or tax model Verdict: DILUTION WATCH Offer premium: 22.0% Equity purchase price: $3,660.0mm Consideration: 65% cash / 35% stock New debt raised: $2,379.0mm New shares issued: 17.1mm Year 1 EPS impact: -1.8% Year 2 EPS impact with $90.0mm after-tax synergies: +3.4% Deterministic flags: - WATCH: deal is Year 1 dilutive before synergies. - WATCH: positive case depends on at least 80% synergy realization. - PASS: sources and uses reconcile to purchase equity value. - MISSING EVIDENCE: transaction expenses, purchase accounting, amortization step-up, integration capex, legal review, tax memo, antitrust analysis, board-process record, and fairness materials are not supplied. - ABSTAIN: no fairness opinion, financing certainty conclusion, legal review, tax structuring memo, antitrust view, or board recommendation can be produced. Safe conclusion: The transaction math is internally consistent under supplied assumptions, but the output is not a fairness opinion or recommendation.
The model will not bless the deal.
Live deterministic API runner; this page computes transaction mechanics from supplied packets while preserving legal, tax, board, and fairness boundaries.
Not investment advice, merger recommendation, legal advice, tax advice, or a fairness opinion.
Does not decide whether a board should approve a transaction or whether consideration is fair from a financial point of view.
Refuses if share counts, offer price, unaffected price, financing terms, tax rate, acquirer EPS, or synergy assumptions are missing.
Separates computed transaction math from diligence topics such as antitrust, fiduciary duties, tax structure, and definitive agreement terms.
Conceptual bakeoff.
Compare an ordinary LLM answer to ALCHEMIST Merger: Paste the COPYABLE MERGER PACKET above into the LLM. Ask the LLM to compute premium, consideration mix, cash paid, new shares, interest burden, and EPS impact using only the source refs supplied. It should preserve the period labels, show where Year 1 differs from Year 2, identify missing purchase-accounting and diligence evidence, refuse to provide a fairness opinion or deal recommendation, and avoid legal, tax, antitrust, financing-certainty, or board-process conclusions.
The control is restraint.
Transaction math: ALCHEMIST Ties premium, purchase equity value, new debt, issued shares, and EPS impact. Ordinary LLM May get premium right but skip the accretion bridge.
Synergy handling: ALCHEMIST Shows Year 1 dilution before synergies and Year 2 uplift with supplied synergies. Ordinary LLM May apply run-rate synergies too early.
Refusal posture: ALCHEMIST ABSTAINS on fairness, board process, legal, tax, and antitrust conclusions. Ordinary LLM Often gives a qualitative approval view.
Boundary: ALCHEMIST Frames the output as deterministic math, not a fairness opinion or deal committee. Ordinary LLM May sound like an advisory memo.
Run the transaction screen.
Edit the transaction packet. The deterministic runner expects unaffected-price support, share counts, financing terms, tax rate, synergy timing, source refs, and missing diligence hooks; it recomputes deal math and refuses fairness, board, tax, legal, antitrust, or financing-certainty conclusions.
Fetching API manifest metadataRunning deterministic API...
Computing verdict, blockers, refusals, metadata, and audit trail.
Bring your own merger packet.
Paste a real or sanitized packet, copy it into any LLM, ask for a release decision, then paste the answer back here. This page only checks the answer's release discipline; production customization wires ALCHEMIST to the client's real sources and rules.
Compute transaction math from supplied facts only; preserve receipts and period labels; refuse fairness opinions, board recommendations, financing-certainty claims, tax/legal/antitrust conclusions, and unsupported synergy certainty.
Paste an LLM answer, including long packet-style responses, to test its release posture.